More than 100 million people across the globe have been infected with COVID-19. Evidence is mounting on long-term neurological and cognitive symptoms that can persist in some COVID-19 patients, including after the virus is no longer detected in the body. Even using the most conservative estimates of the number of COVID-19 survivors that experience cognitive impairments, the numbers are staggering.
Akili digital therapeutic AKL-T01 was purposefully designed to improve cognitive impairments. We are working with leading academic researchers to study AKL-T01 as potential treatment for patients with COVID brain fog.